Bristow M R, Gilbert E M
Division of Cardiology, University of Colorado, Denver 80262, USA.
Eur Heart J. 1995 Jul;16 Suppl F:20-31. doi: 10.1093/eurheartj/16.suppl_f.20.
Virtually all medications used to treat cardiac problems act through a pharmacological mechanism that immediately improves electrical or mechanical function or inhibits the manifestation of a pathological process. The idea that medical therapy could exert a favourable myocardial effect by fundamentally improving the biological function of cardiac myocytes is novel, and is based on the observation that in heart failure the acute pharmacological effects of beta-blocking agents on left ventricular function are completely different from their long-term effects. beta-blocking agents improve intrinsic systolic function long-term, despite depressing function initially through the pharmacological effect of withdrawing adrenergic drive, indicating that the beneficial effect of this form of therapy is due to improved myocyte biology. Implicit in this observation is that improvement in the fundamental biology of failing cardiac myocytes should favourably affect the natural history of heart failure.
几乎所有用于治疗心脏问题的药物都是通过一种药理学机制起作用的,这种机制能立即改善电功能或机械功能,或抑制病理过程的表现。药物治疗可以通过从根本上改善心肌细胞的生物学功能来发挥有利的心肌效应,这一观点是新颖的,它基于这样的观察:在心力衰竭中,β受体阻滞剂对左心室功能的急性药理作用与其长期作用完全不同。β受体阻滞剂长期改善内在收缩功能,尽管最初通过撤回肾上腺素能驱动的药理作用会抑制功能,这表明这种治疗形式的有益效果是由于心肌细胞生物学的改善。这一观察结果所隐含的是,衰竭心肌细胞基本生物学的改善应该会对心力衰竭的自然病程产生有利影响。